{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T21:46:55Z","timestamp":1791841615508,"version":"4.3.4"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Obesity Pillars"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.obpill.2026.100339","type":"journal-article","created":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T23:51:01Z","timestamp":1791417061000},"page":"100339","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Determinants of variable response to GLP-1 receptor agonists: A mechanism-informed framework for precision treatment of obesity"],"prefix":"10.1016","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4141-5187","authenticated-orcid":false,"given":"Samit","family":"Ghosal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.obpill.2026.100339_bib1","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S2213-8587(24)00316-4","article-title":"Definition and diagnostic criteria of clinical obesity","volume":"13","author":"Rubino","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"Suppl 1","key":"10.1016\/j.obpill.2026.100339_bib2","first-page":"S166","article-title":"8. Obesity and weight management for the prevention and treatment of type 2 diabetes: standards of care in Diabetes-2026","volume":"49","year":"2026","journal-title":"Diabetes Care"},{"issue":"12","key":"10.1016\/j.obpill.2026.100339_bib3","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1016\/j.mayocp.2023.05.026","article-title":"Obesity: a review of pathophysiology and classification","volume":"98","author":"Busebee","year":"2023","journal-title":"Mayo Clin Proc"},{"issue":"Suppl 3","key":"10.1016\/j.obpill.2026.100339_bib4","first-page":"S11","article-title":"Central and peripheral regulation of food intake and physical activity: pathways and genes","volume":"16","author":"Lenard","year":"2008","journal-title":"Obesity"},{"issue":"24","key":"10.1016\/j.obpill.2026.100339_bib5","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.obpill.2026.100339_bib6","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.obpill.2026.100339_bib7","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1056\/NEJMoa2413258","article-title":"Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis","volume":"392","author":"Sanyal","year":"2025","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.obpill.2026.100339_bib8","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.obpill.2026.100339_bib9","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.obpill.2026.100339_bib10","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2023.1170181","article-title":"Variation in responses to incretin therapy: modifiable and non-modifiable factors","volume":"10","author":"Austin","year":"2023","journal-title":"Front Mol Biosci"},{"key":"10.1016\/j.obpill.2026.100339_bib11","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2024.1382814","article-title":"Semaglutide for weight loss: unanswered questions","volume":"15","author":"Tzoulis","year":"2024","journal-title":"Front Endocrinol"},{"issue":"4","key":"10.1016\/j.obpill.2026.100339_bib12","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1002\/oby.23120","article-title":"Selection of antiobesity medications based on phenotypes enhances weight loss: a pragmatic trial in an obesity clinic","volume":"29","author":"Acosta","year":"2021","journal-title":"Obesity"},{"issue":"6","key":"10.1016\/j.obpill.2026.100339_bib13","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.amjmed.2025.01.021","article-title":"Mechanisms of GLP-1 receptor agonist-induced weight loss: a review of central and peripheral pathways in appetite and energy regulation","volume":"138","author":"Moiz","year":"2025","journal-title":"Am J Med"},{"issue":"2","key":"10.1016\/j.obpill.2026.100339_bib14","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1210\/endrev\/bnaf036","article-title":"Novel GLP-1-based medications for type 2 diabetes and obesity","volume":"47","author":"Son","year":"2026","journal-title":"Endocr Rev"},{"key":"10.1016\/j.obpill.2026.100339_bib15","doi-asserted-by":"crossref","first-page":"155","DOI":"10.3389\/fendo.2019.00155","article-title":"The discovery and development of liraglutide and semaglutide","volume":"10","author":"Knudsen","year":"2019","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.obpill.2026.100339_bib16","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.addr.2018.07.009","article-title":"Battle of GLP-1 delivery technologies","volume":"130","author":"Yu","year":"2018","journal-title":"Adv Drug Deliv Rev"},{"issue":"5","key":"10.1016\/j.obpill.2026.100339_bib17","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1089\/dia.2023.0491","article-title":"Relationship between lipohypertrophy, glycemic control, and insulin dosing: a systematic meta-analysis","volume":"26","author":"Mader","year":"2024","journal-title":"Diabetes Technol Therapeut"},{"issue":"4","key":"10.1016\/j.obpill.2026.100339_bib18","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.cmet.2018.03.001","article-title":"Mechanisms of action and therapeutic application of glucagon-like Peptide-1","volume":"27","author":"Drucker","year":"2018","journal-title":"Cell Metab"},{"issue":"1","key":"10.1016\/j.obpill.2026.100339_bib19","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/s41392-024-01931-z","article-title":"Glucagon-like peptide-1 receptor: mechanisms and advances in therapy","volume":"9","author":"Zheng","year":"2024","journal-title":"Signal Transduct Targeted Ther"},{"issue":"1","key":"10.1016\/j.obpill.2026.100339_bib20","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S2213-8587(22)00340-0","article-title":"Pharmacogenomics of GLP-1 receptor agonists: a genome-wide analysis of observational data and large randomised controlled trials","volume":"11","author":"Dawed","year":"2023","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"7","key":"10.1016\/j.obpill.2026.100339_bib21","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1002\/oby.24300","article-title":"A GLP1R gene variant and sex influence the response to semaglutide treatment in patients with severe obesity","volume":"33","author":"Phan","year":"2025","journal-title":"Obesity"},{"issue":"1","key":"10.1016\/j.obpill.2026.100339_bib22","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1038\/s41467-018-03941-2","article-title":"Targeting GLP-1 receptor trafficking to improve agonist efficacy","volume":"9","author":"Jones","year":"2018","journal-title":"Nat Commun"},{"issue":"12","key":"10.1016\/j.obpill.2026.100339_bib23","doi-asserted-by":"crossref","first-page":"4186","DOI":"10.2337\/db14-0849","article-title":"GLP-1 receptor activation modulates appetite- and reward-related brain areas in humans","volume":"63","author":"van Bloemendaal","year":"2014","journal-title":"Diabetes"},{"key":"10.1016\/j.obpill.2026.100339_bib24","doi-asserted-by":"crossref","first-page":"181","DOI":"10.3389\/fnins.2013.00181","article-title":"The central GLP-1: implications for food and drug reward","volume":"7","author":"Skibicka","year":"2013","journal-title":"Front Neurosci"},{"issue":"4","key":"10.1016\/j.obpill.2026.100339_bib25","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20231385","article-title":"Anorexigenic neuropeptides as anti-obesity and neuroprotective agents: exploring the neuroprotective effects of anorexigenic neuropeptides","volume":"44","author":"Strnadov\u00e1","year":"2024","journal-title":"Biosci Rep"},{"issue":"1","key":"10.1016\/j.obpill.2026.100339_bib26","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1172\/JCI59660","article-title":"Obesity is associated with hypothalamic injury in rodents and humans","volume":"122","author":"Thaler","year":"2012","journal-title":"J Clin Investig"},{"key":"10.1016\/j.obpill.2026.100339_bib27","article-title":"Actions of feeding-related peptides on the mesolimbic dopamine system in regulation of natural and drug rewards","volume":"2","author":"Dunigan","year":"2022","journal-title":"Addict Neurosci"},{"key":"10.1016\/j.obpill.2026.100339_bib28","doi-asserted-by":"crossref","DOI":"10.3389\/fnbeh.2020.614884","article-title":"Can GLP-1 be a target for reward system related disorders? A qualitative synthesis and systematic review analysis of studies on palatable food, drugs of abuse, and alcohol","volume":"14","author":"Eren-Yazicioglu","year":"2021","journal-title":"Front Behav Neurosci"},{"issue":"9","key":"10.1016\/j.obpill.2026.100339_bib29","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1002\/oby.23236","article-title":"Correction: selection of antiobesity medications based on phenotypes enhances weight loss: a pragmatic trial in an obesity clinic","volume":"29","author":"Acosta","year":"2021","journal-title":"Obesity"},{"key":"10.1016\/j.obpill.2026.100339_bib30","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2023.1187735","article-title":"Visceral adipose tissue and residual cardiovascular risk: a pathological link and new therapeutic options","volume":"10","author":"Cesaro","year":"2023","journal-title":"Front Cardiovasc Med"},{"issue":"3","key":"10.1016\/j.obpill.2026.100339_bib31","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","article-title":"European association for the study of diabetes (EASD), european association for the study of obesity (EASO). EASL-EASD-EASO clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"81","year":"2024","journal-title":"J Hepatol"},{"issue":"5","key":"10.1016\/j.obpill.2026.100339_bib32","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1093\/jn\/135.5.1314","article-title":"Obesity and the neuroendocrine control of energy homeostasis: the role of spontaneous locomotor activity","volume":"135","author":"Casta\u00f1eda","year":"2005","journal-title":"J Nutr"},{"issue":"Suppl 1","key":"10.1016\/j.obpill.2026.100339_bib33","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1038\/ijo.2010.184","article-title":"Adaptive thermogenesis in humans","volume":"34","author":"Rosenbaum","year":"2010","journal-title":"Int J Obes"},{"issue":"Suppl 1","key":"10.1016\/j.obpill.2026.100339_bib34","article-title":"2610-P: pathophysiological obesity phenotype-guided evaluation of efficacy and safety for GLP-1RA","volume":"75","author":"Wang","year":"2026","journal-title":"Diabetes"},{"issue":"7","key":"10.1016\/j.obpill.2026.100339_bib35","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.3390\/biomedicines12071493","article-title":"The triglyceride\/HDL ratio as a surrogate biomarker for insulin resistance","volume":"12","author":"Baneu","year":"2024","journal-title":"Biomedicines"},{"issue":"3","key":"10.1016\/j.obpill.2026.100339_bib36","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/j.1467-789X.2011.00952.x","article-title":"Waist-to-height ratio is a better screening tool than waist circumference and BMI for adult cardiometabolic risk factors: systematic review and meta-analysis","volume":"13","author":"Ashwell","year":"2012","journal-title":"Obes Rev"},{"key":"10.1016\/j.obpill.2026.100339_bib37","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.biochi.2024.10.012","article-title":"Central nervous system pathways targeted by amylin in the regulation of food intake","volume":"229","author":"Hankir","year":"2025","journal-title":"Biochimie"},{"issue":"10317","key":"10.1016\/j.obpill.2026.100339_bib38","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1016\/S0140-6736(21)01751-7","article-title":"Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial","volume":"398","author":"Lau","year":"2021","journal-title":"Lancet"},{"issue":"10403","key":"10.1016\/j.obpill.2026.100339_bib39","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/S0140-6736(23)01163-7","article-title":"Efficacy and safety of co-administered once-weekly cagrilintide 2.4 mg with once-weekly semaglutide 2.4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial","volume":"402","author":"Frias","year":"2023","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.obpill.2026.100339_bib40","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1016\/j.cmet.2024.05.010","article-title":"Tirzepatide modulates the regulation of adipocyte nutrient metabolism through long-acting activation of the GIP receptor","volume":"36","author":"Regmi","year":"2024","journal-title":"Cell Metab"},{"issue":"21","key":"10.1016\/j.obpill.2026.100339_bib41","doi-asserted-by":"crossref","first-page":"5407","DOI":"10.3390\/ijms20215407","article-title":"Glucagon regulation of energy expenditure","volume":"20","author":"Kleinert","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"6","key":"10.1016\/j.obpill.2026.100339_bib42","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa2301972","article-title":"Triple-hormone-receptor agonist retatrutide for Obesity\u2014a phase 2 trial","volume":"389","author":"Jastreboff","year":"2023","journal-title":"N Engl J Med"}],"container-title":["Obesity Pillars"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667368126000951?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667368126000951?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T21:08:38Z","timestamp":1791839318000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2667368126000951"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":42,"alternative-id":["S2667368126000951"],"URL":"https:\/\/doi.org\/10.1016\/j.obpill.2026.100339","relation":{},"ISSN":["2667-3681"],"issn-type":[{"value":"2667-3681","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Determinants of variable response to GLP-1 receptor agonists: A mechanism-informed framework for precision treatment of obesity","name":"articletitle","label":"Article Title"},{"value":"Obesity Pillars","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.obpill.2026.100339","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author. Published by Elsevier Inc. on behalf of Obesity Medicine Association.","name":"copyright","label":"Copyright"}],"article-number":"100339"}}